In a big disappointment for 340B hospital organizations, the U.S. Centers for Medicare & Medicaid Services (CMS) announced late this afternoon that it will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs and biologicals for 2022.
Rural sole community hospitals, children’s hospitals, and free-standing cancer hospitals will remain exempt from CMS’s 340B payment policy for separately payable drugs with non-pass-through status. CMS made the decision to retain the drug payment cut for many 340B hospitals in its calendar year 2022 hospital Outpatient Prospective Payment System (OPPS) final rule with comment. CMS released its OPPS final rule for public inspection late this afternoon.
In a big disappointment for 340B hospital organizations, the U.S. Centers for Medicare & Medicaid Services (CMS) announced late this afternoon that it will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs and biologicals for 2022.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
